We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

97 hedge funds and large institutions have $441M invested in CytomX Therapeutics in 2017 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 16 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 16

53% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 15

29% more capital invested

Capital invested by funds: $343M → $441M (+$98M)

8% more funds holding

Funds holding: 90 → 97 (+7)

5.6% more ownership

Funds ownership: 60.15% → 65.75% (+5.6%)

0% more call options, than puts

Call options by funds: $1K | Put options by funds: $1K

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
97
Holders Change
+7
Holders Change %
+7.78%
% of All Funds
2.42%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
23
Increased
38
Reduced
16
Closed
15
Calls
$1K
Puts
$1K
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$8.15M
2
State Street
State Street
Massachusetts
+$6.36M
3
BlackRock
BlackRock
New York
+$3.86M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.5M
5
BI
BVF Inc
California
+$3.18M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$4.93M
2
DCM
Driehaus Capital Management
Illinois
-$4.5M
3
VMI
VHCP Management II
New York
-$4.48M
4
EAM
Eventide Asset Management
Massachusetts
-$2.33M
5
CAM
Cormorant Asset Management
Massachusetts
-$2.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
VOYA Investment Management
76
VOYA Investment Management
Georgia
$238K – – –
D.E. Shaw & Co
77
D.E. Shaw & Co
New York
$227K +$195K +12,483 New
Jacobs Levy Equity Management
78
Jacobs Levy Equity Management
New Jersey
$223K +$191K +12,250 New
VF
79
Virtu Financial
New York
$223K +$192K +12,291 New
FQ
80
First Quadrant
California
$155K -$28.6K -1,835 -18%
Legal & General Group
81
Legal & General Group
United Kingdom
$131K +$12.5K +798 +12%
DCM
82
DAFNA Capital Management
California
$107K +$92.1K +5,900 New
Macquarie Group
83
Macquarie Group
Australia
$107K +$92.1K +5,900 New
MCM
84
Manchester Capital Management
Vermont
$59K – – –
BNP Paribas Financial Markets
85
BNP Paribas Financial Markets
France
$56.4K -$2.76K -177 -5%
Royal Bank of Canada
86
Royal Bank of Canada
Ontario, Canada
$45K +$37.9K +2,427 +5,393%
AIP
87
Ameritas Investment Partners
Nebraska
$44K – – –
Canada Life
88
Canada Life
Manitoba, Canada
$32K – – –
Acadian Asset Management
89
Acadian Asset Management
Massachusetts
$29K -$39.4K -2,524 -61%
TRCT
90
Tower Research Capital (TRC)
New York
$28K +$23.5K +1,508 New
Fifth Third Bancorp
91
Fifth Third Bancorp
Ohio
$27K – – –
MAM
92
Meeder Asset Management
Ohio
$13K +$6.76K +433 +156%
RA
93
Royce & Associates
New York
$8K +$6.88K +441 New
QI
94
QS Investors
New York
$7K +$5.77K +370 New
Simplex Trading
95
Simplex Trading
Illinois
$5K +$4.53K +290 New
AWMS
96
Advocacy Wealth Management Services
Georgia
$2K – – –
TWA
97
TCI Wealth Advisors
Arizona
$2K +$1.56K +100 New
DCM
98
Driehaus Capital Management
Illinois
– -$4.5M -290,415 Closed
VMI
99
VHCP Management II
New York
– -$4.48M -288,915 Closed
EAM
100
Eventide Asset Management
Massachusetts
– -$2.33M -150,000 Closed
1 2 3
4
5

CTMX Hedge Fund Activity: Q3 2017 in Review

97 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2017, worth a combined $441M — up 29% from $343M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CTMX positions and 15 closed out — a net gain of 8 holders — while 38 added to existing stakes and 16 trimmed.

The largest buyer was Millennium Management, adding an estimated $8.15M. The largest seller was Redmile Group, cutting an estimated $4.93M.

  • 97 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2017, up from 90 in Q2 2017.
  • Funds reported $441M of CytomX Therapeutics stock for Q3 2017, up 29% quarter-over-quarter.
  • 23 funds opened new CytomX Therapeutics positions in Q3 2017 and 15 closed out, a net change of +8 holders.
  • The largest CytomX Therapeutics buyer in Q3 2017 was Millennium Management, an estimated $8.15M added.
  • The largest CytomX Therapeutics seller in Q3 2017 was Redmile Group, an estimated $4.93M sold.

Based on aggregated 13F filings for Q3 2017.